Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey
- PMID: 7849490
- DOI: 10.1089/ard.1994.4.201
Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey
Abstract
Rapid intravenous infusion of GEM 91, a 25-mer phosphorothioate oligonucleotide complementary to the gag site of HIV, in the monkey produces transient decreases in peripheral total WBC and neutrophil counts, hemoconcentration, and a brief increase followed by a prolonged decrease in arterial blood pressure. These changes are preceded by and are likely mediated by activation of C5 complement. These effects are dose and infusion rate dependent and can be avoided by administering GEM 91 by slow intravenous infusion. Similar hemodynamic effects are produced with rapid intravenous infusion of other phosphorothioate oligonucleotides varying in length from 20- to 33-mer, and are, therefore, not sequence specific but a property of this chemical structure.
Similar articles
-
Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide.Int Immunopharmacol. 2002 Nov;2(12):1657-66. doi: 10.1016/s1567-5769(02)00142-x. Int Immunopharmacol. 2002. PMID: 12469940
-
Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys.Antisense Nucleic Acid Drug Dev. 2001 Jun;11(3):155-63. doi: 10.1089/108729001300338681. Antisense Nucleic Acid Drug Dev. 2001. PMID: 11446591
-
Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys.J Pharmacol Exp Ther. 1996 Sep;278(3):1306-12. J Pharmacol Exp Ther. 1996. PMID: 8819516
-
In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue.Anticancer Drug Des. 1991 Dec;6(6):531-8. Anticancer Drug Des. 1991. PMID: 1772568 Review.
-
Pharmacokinetics of antisense oligonucleotides.Clin Pharmacokinet. 1995 Jan;28(1):7-16. doi: 10.2165/00003088-199528010-00002. Clin Pharmacokinet. 1995. PMID: 7712663 Review.
Cited by
-
RNA Therapeutics Are Stepping Out of the Maze.Trends Mol Med. 2020 Dec;26(12):1061-1064. doi: 10.1016/j.molmed.2020.08.007. Epub 2020 Sep 25. Trends Mol Med. 2020. PMID: 32988738 Free PMC article. Review.
-
Introduction and History of the Chemistry of Nucleic Acids Therapeutics.Methods Mol Biol. 2022;2434:3-31. doi: 10.1007/978-1-0716-2010-6_1. Methods Mol Biol. 2022. PMID: 35213007 Free PMC article.
-
Lipid nanoparticle delivery limits antisense oligonucleotide activity and cellular distribution in the brain after intracerebroventricular injection.Mol Ther Nucleic Acids. 2023 May 9;32:773-793. doi: 10.1016/j.omtn.2023.05.005. eCollection 2023 Jun 13. Mol Ther Nucleic Acids. 2023. PMID: 37346977 Free PMC article.
-
The Evolution of Antisense Oligonucleotide Chemistry-A Personal Journey.Biomedicines. 2021 May 3;9(5):503. doi: 10.3390/biomedicines9050503. Biomedicines. 2021. PMID: 34063675 Free PMC article. Review.
-
Preclinical and clinical pharmacology of antisense oligonucleotides.Mol Biotechnol. 1999 Aug;12(1):1-11. doi: 10.1385/MB:12:1:1. Mol Biotechnol. 1999. PMID: 10554769 Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous